University of Rochester Medical Center, Rochester, NY, USA.
Curr Hypertens Rep. 2017 Jan;19(1):4. doi: 10.1007/s11906-017-0702-9.
The increasing prevalence of hypertension, a significant cause of disability and premature death throughout the world, is a major public health concern. This is especially true for the subset of patients who suffer from resistant hypertension, which is associated with a fourfold greater risk of cardiovascular events as compared to those hypertensive patients able to achieve target blood pressure. Though quite daunting in number and ill effect, hypertension remains the most common and the most important modifiable risk factor for coronary heart disease, congestive heart failure, peripheral vascular disease, stroke, and chronic kidney disease. Therefore, the ongoing development of novel therapies for the management of hypertension is of utmost importance. This review evaluates the present and future of interventional treatment of resistant hypertension, most of which remains investigational and warrants critical assessment.
高血压的患病率不断上升,是全世界致残和早逝的主要原因之一,这是一个重大的公共卫生关注点。对于那些患有难治性高血压的患者来说,情况更是如此,与那些能够达到目标血压的高血压患者相比,他们患心血管事件的风险高出四倍。尽管高血压的数量和不良影响令人望而生畏,但它仍然是冠心病、充血性心力衰竭、外周血管疾病、中风和慢性肾病最常见和最重要的可改变危险因素。因此,不断开发治疗高血压的新疗法至关重要。本综述评估了难治性高血压的介入治疗的现状和未来,其中大部分仍处于研究阶段,需要进行批判性评估。